Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT04362839 |
TitleRegorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer | 阶段
第 1 阶段
|
Date Added 2020-04-27 |
地点
California, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Ipilimumab, Nivolumab, Regorafenib, Opdivo, Stivarga, Yervoy |
标签
MSS/ MMRp
|
| NCT ID NCT04332653 |
TitleNT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | 阶段
第 1 阶段
|
Date Added 2020-04-03 |
地点
Florida, United States
Michigan, United States Missouri, United States North Carolina, United States Pennsylvania, United States Tennessee, United States Texas, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
NT-I7, Pembrolizumab |
标签
MSS/ MMRp
|
| NCT ID NCT04262687 |
TitleChemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate | 阶段
第二阶段
|
Date Added 2020-02-10 |
地点
法国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Bevacizumab, capecitabine, oxaliplatin, Pembrolizumab |
标签
MSS/ MMRp
|
| NCT ID NCT04185883 |
TitleSotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | 阶段
第 1 阶段
|
Date Added 2019-12-04 |
地点
Arizona, United States
California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Maryland, United States Michigan, United States Missouri, United States New York, United States North Carolina, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States 澳大利亚 Austria 比利时 加拿大 德国 意大利 日本 大韩民国 荷兰 西班牙 台湾 英国 |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
afatinib, AMG 404, Atezolizumab, carboplatin, pemetrexed, docetaxel, everolimus, FOLFIRI, FOLFOX, MVASI® (bevacizumab-awwb), palbociclib, panitumumab, Pembrolizumab, RMC-4630, Sotorasib, TNO155, Trametinib |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04130854 |
TitleINNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer | 阶段
第二阶段
|
Date Added 2019-10-18 |
地点
Arizona, United States
North Carolina, United States Oregon, United States Texas, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days, mFOLFOX and Radiation Therapy 5Gy x 5 days |
标签
MSS/ MMRp
|
| NCT ID NCT04117087 |
TitlePooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer | 阶段
第 1 阶段
|
Date Added 2019-10-07 |
地点
Maryland, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Ipilimumab, Nivolumab, Opdivo, Yervoy |
标签
MSS/ MMRp
|
| NCT ID NCT04110093 |
Title瑞戈非尼加 PD-1 抑制剂治疗结直肠癌患者 | 阶段
第 1 阶段/第 2 阶段
|
Date Added 2019-10-01 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
瑞戈非尼和 PD-1 抑制剂 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04111172 |
Title用于治疗胃肠道腺癌的疫苗（Ad5.F35-hGCC-PADRE） | 阶段
第二阶段
|
Date Added 2019-10-01 |
地点
Pennsylvania, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
腺病毒 5/F35-人鸟苷酸环化酶 C-PADRE |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04111458 |
TitleA Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) | 阶段
第 1 阶段
|
Date Added 2019-10-01 |
地点
Massachusetts, United States
North Carolina, United States Tennessee, United States Texas, United States 德国 荷兰 |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
BI 1701963, Trametinib |
标签
MSS/ MMRp
|
| NCT ID NCT04104776 |
TitleCPI-0209 对晚期实体瘤和淋巴瘤患者的研究 | 阶段
第 1 阶段
|
Date Added 2019-09-26 |
地点
Georgia, United States
Illinois, United States Maryland, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Texas, United States Virginia, United States Washington, United States 法国 意大利 大韩民国 波兰 西班牙 英国 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物
CPI-0209, CPI-0209 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
